Roche names Eli Lilly executive Levi Garraway as chief medical officer

Levi Garraway, most recently Eli Lilly's senior vice president, oncology research and development and Lilly research laboratories novel target research, will take up the post as of Oct. 1 and be based in South San Francisco.

ZURICH: Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as a chief medical officer and head of global product development.

Garraway, most recently Eli Lilly's senior vice president, oncology research and development and Lilly research laboratories novel target research, will take up the post as of Oct. 1 and be based in South San Francisco.

Horning, who joined Roche and its Genentech division nearly a decade ago and has been the chief medical officer since 2014, will retire as of the end of 2019, Roche said in a statement.

She led the product development organization, oversaw late-stage clinical development, and co-chaired the committee that invests in pivotal registrational trials.

Read Also: Roche personalized cancer treatment Rozlytrek priced at Rs 12 lakh per month

Garraway joined Lilly in 2017 as senior vice president, global development and medical affairs for the oncology division. Before that, he was a director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals.

In 2010, Garraway, a Harvard graduate, co-founded Foundation Medicine, which provides tumour molecular information.

Read Also: Single dose of Xofluza flu drug as effective as Tamiflu in kids, says Roche